P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials

• Andrea Doria,
• Diogo Jesus,
• Ana Matos,
• Carla Henriques,
• Luís Sousa Inês

Affiliations

Andrea Doria

1Department of Medicine, University of Padua, Italy

Diogo Jesus

Rheumatology Department, Leiria Hospital Centre, Pousos, Portugal

Ana Matos

5Research Centre in Digital Services (CISeD), Viseu, Portugal

Carla Henriques

3School of Technology and Management, Polytechnic Institute of Viseu, Viseu, Portugal

Luís Sousa Inês

7CHUC Lupus Clinic, Rheumatology Dept., Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal